Effect of fluvoxamine and N-methyl-D-aspartate receptor antagonists on shock-induced depression in mice.
We have earlier demonstrated that NMDA receptor antagonists possess antidepressant effect and also they show a synergism with imipramine. The present study attempts to investigate whether NMDA receptor antagonists also interact with selective serotonin reuptake inhibitors. The study was conducted in albino mice using shock-induced depression model. The mice were placed on a grid floor and shock delivered were of 2 sec duration with a 9 sec interval for 1 h. Twenty four hours later depression was measured by an open field test followed by a forced swimming test. Presentation of inescapable foot shock significantly reduced ambulation (from 159.50 +/- 5.42 to 80.50 +/- 4.61) and rearing (from 22.10 +/- 2.15 to 11.30 +/- 1.32) in the open field arena and increased immobility duration in the forced swimming test (from 82.20 +/- 3.51 to 158.90 +/- 4.61). Pretreatment with fluvoxamine, MK-801, ketamine and the combination of fluvoxamine with either of the NMDA antagonists antagonised shock-induced depression. Haloperidol and ketanserin pretreatment modified the effect of these agents. These findings suggest an interaction of NMDA receptor antagonists with fluvoxamine, and an involvement of brain dopaminergic and tryptaminergic mechanisms in the behavioural suppression observed after inescapable foot shock.
Chaturvedi
H K
HK
Department of Pharmacology, Maulana Azad Medical College, New Delhi-110 002.
Bapna
J S
JS
Chandra
D
D
D000818:Animals; D003863:Depression / Q000188:drug therapy*; D016291:Dizocilpine Maleate / Q000627:therapeutic use; D004357:Drug Synergism; D004597:Electroshock; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use*; D005260:Female; D016666:Fluvoxamine / Q000627:therapeutic use*; D007649:Ketamine / Q000627:therapeutic use; D008297:Male; D051379:Mice; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*
D016291:Dizocilpine Maleate; D018691:Excitatory Amino Acid Antagonists; D016666:Fluvoxamine; D007649:Ketamine; D016194:Receptors, N-Methyl-D-Aspartate; D017367:Selective Serotonin Reuptake Inhibitors